• Warning signs in the market     Monday, 24 Mar 2014 | 12:00 PM ET

    The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.

  • What's working in biotech: CELG, ALXN & more     Monday, 24 Mar 2014 | 8:05 AM ET

    U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.

  • Analyst likes large cap biotechs     Friday, 21 Mar 2014 | 2:06 PM ET

    Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.

  • Biotech weighs on S&P     Friday, 21 Mar 2014 | 1:02 PM ET

    CNBC's Dominic Chu reports the health care sector is being dragged down by the biotech sector. Congressional Democrats asked biotech company Gilead to provide insight on pricing for its hepatitis C drug Sovaldi.

  • US Democrats ask Gilead about pricing     Friday, 21 Mar 2014 | 12:30 PM ET

    CNBC's Sheila Dharmarajan reports on the decline in the Nasdaq because of the hit to the biotechs. Gilead received a letter from senior Democrats requesting a briefing on the pricing for its hepatitis C drug Sovaldi.

  • MediWound makes US market debut     Thursday, 20 Mar 2014 | 10:48 AM ET

    MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.

  • Pisani: Momentum names holding up     Friday, 14 Mar 2014 | 3:42 PM ET

    CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.

  • Biotech bubble formation?     Friday, 14 Mar 2014 | 12:46 PM ET

    CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.

  • XBI is 'best way to biotech': Trader     Wednesday, 12 Mar 2014 | 12:45 PM ET

    FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.

  • Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.

  • Buy Regeneron today: Pro     Wednesday, 5 Mar 2014 | 2:40 PM ET

    Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.

  • Hot health care trades     Tuesday, 25 Feb 2014 | 12:15 PM ET

    CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.

  • Best biotech stock plays     Thursday, 20 Feb 2014 | 2:40 PM ET

    Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.

  • Pharma for man's best friend     Monday, 10 Feb 2014 | 3:17 PM ET

    Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.

  • Biotech boom keeps going     Wednesday, 29 Jan 2014 | 1:45 PM ET

    CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.

  • LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a simple way to reprogramme mature animal cells back into an embryonic-like state that allows them to generate many types of tissue.

  • LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a cheap and easy way to reprogramme mature cells from mice back into an embryonic-like state that allowed them to generate many types of tissue.

  • As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.

  • Biotech: 2014's favored child     Thursday, 16 Jan 2014 | 12:15 PM ET

    Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.

  • Twitter almost impossible to value: Analyst     Tuesday, 14 Jan 2014 | 10:50 AM ET

    Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.

Most Popular Video

Thursday, 17 Apr 2014 | 1:00 PM ET

Secretary of State John Kerry comments after a meeting in Geneva with Russian Foreign Minister Sergey Lavrov and representatives of the EU and Ukraine.

Thursday, 17 Apr 2014 | 11:40 AM ET

CNBC's Dominic Chu and Art Cashin, of UBS, discuss market fluctuations over the last week, as well as the credible reversal rally. He's still keeping an eye on Ukraine, and says there may be economic fallout if there are new sanctions against Russia.

Thursday, 17 Apr 2014 | 12:09 PM ET

CNBC's Scott Cohn reports Hampshire Hotel CEO Sant Singh Chatwal pleaded guilty in a campaign scheme.